These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 26065480)
1. Adoptive therapy for EBV-induced cancers: driving success with post-transplant lymphoproliferative disorder to other EBV-derived tumors. Smith C; Khanna R Immunotherapy; 2015; 7(5):563-72. PubMed ID: 26065480 [TBL] [Abstract][Full Text] [Related]
2. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Davis JE; Moss DJ Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802 [TBL] [Abstract][Full Text] [Related]
3. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498 [TBL] [Abstract][Full Text] [Related]
5. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for Epstein-Barr virus-associated tumors. Comito MA; Sun Q; Lucas KG Leuk Lymphoma; 2004 Oct; 45(10):1981-7. PubMed ID: 15370241 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833 [TBL] [Abstract][Full Text] [Related]
16. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection. Mautner J; Bornkamm GW Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882 [TBL] [Abstract][Full Text] [Related]
18. Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. Tse E; Kwong YL Exp Mol Med; 2015 Jan; 47(1):e136. PubMed ID: 25613733 [TBL] [Abstract][Full Text] [Related]
19. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma. Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapeutic strategies for EBV-associated malignancies. Khanna R; Tellam J; Duraiswamy J; Cooper L Trends Mol Med; 2001 Jun; 7(6):270-6. PubMed ID: 11378517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]